Clinical Trials Sponsored by Celldex Therapeutics

Total 6359 results

Grene Vision Group
Ocular Therapeutix, Inc.

Completed

The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1

Cataract

United States
The Cleveland Clinic
Ocular Therapeutix, Inc.

Enrolling by invitation

Dextenza in the Post-op Management of Vitreoretinal Surgeries

Ocular Inflammation | Post-operative Pain | Vitreoretinal Surgery | Post-Operative Inflammation

United States
New England Retina Associates
Ocular Therapeutix

Unknown

Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids (DiverT)

Non-infectious Anterior Uveitis
Eli Lilly and Company
Alzheimer's Therapeutic Research Institute

Completed

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)

Cognition Disorders

United States, Canada, Australia, Japan
Alfa Intes Industria Terapeutica Splendore s.r.l.

Not yet recruiting

Idroflog® for Treatment of Dry Eye Disease (IDROFLOG) (IDROFLOG)

Dry Eye Disease

France
Tufts Medical Center
Ocular Therapeutix, Inc.

Recruiting

Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) (DEcIDED)

Dry Eye

United States
Vance Thompson Vision
Ocular Therapeutix, Inc.

Completed

The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study

Refractive Surgery

United States
Silverstein Eye Centers
Ocular Therapeutix, Inc.

Completed

Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery

Cataract Surgery

United States
Prism Vision Group
Ocular Therapeutix, Inc.

Unknown

Pre-Surgical Ocular Surface Treatment With Intracanalicular Dexamethasone Insert And Effect On Intraocular Lens Measurement Accuracy

Ocular Surface Disease | Dry Eye Disease | Cataract Surgery
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Eli Lilly and Company; Genentech, Inc.; Kazia... and other collaborators

Recruiting

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | NTRK Family Gene Mutation | CDK Gene Mutation | PI3K Gene Mutation | ROS1 Gene Mutation | KRAS G12C Mutation

United States
Swiss Dental Solutions
VISTA Institute for Therapeutic Innovations

Enrolling by invitation

Zirconia Implants: Practice-based Evidence (SDS)

Dental Implants | Ceramic Implant

United States
Therapeutic Advances in Childhood Leukemia Consortium
GlaxoSmithKline; Novartis

Terminated

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Relapsed T-Cell Acute Lymphoblastic Leukemia | Relapsed T-Cell Lymphoblastic Lymphoma

United States, France, Canada, Australia, Austria, Italy, Netherlands
Johns Hopkins University
National Multiple Sclerosis Society; Axsome Therapeutics, Inc.

Recruiting

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue (SOLARIMS)

Multiple Sclerosis | Multiple Sclerosis Fatigue

United States
Aardvark Therapeutics, Inc.
Center for Psychiatry And Behavioral Medicine Inc.

Recruiting

A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder

Autism Spectrum Disorder

United States
Sir Run Run Shaw Hospital
Hangzhou Neoantigen Therapeutics Co., Ltd.

Recruiting

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms

Digestive System Neoplasms

China
HuidaGene Therapeutics Co., Ltd.
Eye & ENT Hospital of Fudan University

Not yet recruiting

a Study in Subjects With Otoferlin Mutation-related Hearing Loss Using RNA Base-eDiting Therapy(SOUND) (SOUND)

Congenital Hearing Loss

China
Merz Therapeutics GmbH
Heinrich-Heine University, Duesseldorf

Recruiting

Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia (RELY-CD)

Cervical Dystonia

Germany
Centessa Pharmaceuticals (UK) Limited
LockBody Therapeutics Ltd

Recruiting

A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors

Advanced Solid Tumor

United States, France
The First Affiliated Hospital of Soochow University
Fundamenta Therapeutics, Ltd.

Recruiting

ThisCART19A Bridging to alloHSCT for R/R B-ALL

CAR | Refractory Acute Lymphoblastic Leukemia | Relapsed Adult ALL

China
The Affiliated People's Hospital of Ningbo University
UTC Therapeutics Inc.

Recruiting

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Lymphoma | Leukemia | Myeloma | Relapsed/Refractory Hematological Malignancies

China
Fundamenta Therapeutics, Ltd.
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

B-cell Malignancy

China
Fundamenta Therapeutics, Ltd.
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

B-cell Malignancy

China
Rahul Aggarwal
Fortis Therapeutics, Inc.

Recruiting

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Juan P. Alderuccio, MD
ADC Therapeutics S.A.

Recruiting

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

United States
Lakshmi Nayak, MD
Kazia Therapeutics Limited

Recruiting

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Primary Central Nervous System Lymphoma | Non-Hodgkin Lymphoma of Extranodal Site

United States
AlaMab Therapeutics (Shanghai) Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

Osteosarcoma
Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Cellphire Therapeutics, Inc.
U.S. Army Medical Research and Development Command

Recruiting

DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS) (CRYPTICS)

Cardiac Surgery

United States
Allarity Therapeutics
Smerud Medical Research International AS; Lantern Pharma Inc.

Active, not recruiting

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Metastatic Castration-Resistant Prostate Cancer Patients

Denmark
Jeff C. Huffman, MD
BioXcel Therapeutics Inc

Withdrawn

Dexmedetomidine Sublingual Film for the Management of Agitation in Delirium: Safety and Preliminary Efficacy

Delirium
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); Highlight Therapeutics

Active, not recruiting

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Leiomyosarcoma | Malignant Peripheral Nerve Sheath Tumor | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Undifferentiated High Grade Pleomorphic Sarcoma of Bone | Myxofibrosarcoma | Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the... and other conditions

United States
Kinoxis Therapeutics Pty Ltd
National Institute on Drug Abuse (NIDA)

Completed

A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers (KTX101)

Opioid-use Disorder | Healthy Volunteer Study

Australia
Horizon Therapeutics Ireland DAC

Completed

Study to Evaluate HZN-457 in Healthy Volunteers

Healthy

New Zealand
Memorial Sloan Kettering Cancer Center
Halozyme Therapeutics; Miami Cancer Institute

Active, not recruiting

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Pancreatic Cancer | Advanced Pancreatic Ductal Adenocarcinoma

United States
Y-mAbs Therapeutics
Invicro; Labcorp Corporation of America Holdings, Inc

Withdrawn

131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma

DIPG
University of Pennsylvania
Parker Institute for Cancer Immunotherapy; Tmunity Therapeutics

Terminated

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Melanoma | Multiple Myeloma | Myxoid/Round Cell Liposarcoma | Synovial Sarcoma

United States
Merit E. Cudkowicz, MD
Denali Therapeutics Inc.

Enrolling by invitation

HEALEY ALS Platform Trial - Regimen G DNL343

Amyotrophic Lateral Sclerosis

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Highlight Therapeutics

Terminated

BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

Advanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Refractory Hepatocellular Carcinoma

United States
Chandrikha Chandrasekhara
TerSera Therapeutics LLC

Withdrawn

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl (NET-PACS)

Diarrhea | Neuroendocrine Tumors | Carcinoid Syndrome

United States
Guru P. Sonpavde
QED Therapeutics, Inc.

Withdrawn

Phase I BLASST-3 Trial ((BLASST)-3)

Bladder Cancer | Bladder Transitional Cell Carcinoma | Fibroblast Growth Factor Receptor
Translational Research in Oncology
Stand Up To Cancer; Effector Therapeutics

Completed

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer

Breast Cancer

Canada
Tulane University School of Medicine
Karyopharm Therapeutics Inc

Withdrawn

Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma (ESdRRMM)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma
Jonathan Stine
Grifols Therapeutics LLC

Withdrawn

Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis (PiVoT)

Cirrhosis, Liver | Portal Vein Thrombosis

United States
Sir Run Run Shaw Hospital
Hangzhou Neoantigen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor

Advanced Malignant Solid Tumor

China
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Public Health Clinical Center

Active, not recruiting

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma

Renal Cell Carcinoma

China
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

Attention Deficit Disorder With Hyperactivity

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

Attention Deficit Hyperactivity Disorder

United States
Pain Therapeutics
National Institute on Aging (NIA)

Completed

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Alzheimer Disease

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations

Attention Deficit Hyperactivity Disorder

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Io Therapeutics

Terminated

Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States

Clinical Trials Sponsored by Celldex Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations